Responses
Clinical and epidemiological research
Extended report
A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)
Compose a Response to This Article
Other responses
No responses have been published for this article.